Showing 1,841 - 1,860 results of 1,976 for search '"Ben Gurion University of the Negev"', query time: 0.13s Refine Results
  1. 1841
  2. 1842
  3. 1843
  4. 1844
  5. 1845
  6. 1846
  7. 1847
  8. 1848
  9. 1849
  10. 1850
  11. 1851

    Clinical Outcomes of Patients with HER2 Positive Metastatic Breast Cancer to the Brain, with First-Line Trastuzumab, Pertuzumab and Chemotherapy, in a Real-World Setting by Sharman Moser S, Apter L, Livnat I, Ginsburg R, Yarden A, Drori M, Drizon A, Chodick G, Siegelmann-Danieli N

    Published 2024-03-01
    “…Sarah Sharman Moser,1 Lior Apter,1,2 Idit Livnat,3 Roni Ginsburg,3 Adva Yarden,3 Michal Drori,1 Anat Drizon,1 Gabriel Chodick,1,4 Nava Siegelmann-Danieli1,4 1Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; 2Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel; 3Medical Affairs, AstraZeneca, Kefar Sava, Israel; 4Faculty of Medicine, Tel Aviv University, Tel Aviv, IsraelCorrespondence: Sarah Sharman Moser, Email moser_sa@mac.org.ilBackground: In this observational study, we analyzed the treatment patterns and clinical outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) who developed brain metastases during their disease in a 2.7 million-member public health-provider in Israel.Methods: Newly diagnosed patients with mBC who initiated first-line treatment between January 2013 and June 2021 were identified. …”
    Get full text
    Article
  12. 1852
  13. 1853
  14. 1854
  15. 1855
  16. 1856
  17. 1857
  18. 1858
  19. 1859
  20. 1860